Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.531 mg - antithrombotic agents

Malta - English - Medicines Authority

glaxo wellcome uk limited - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.5 mg - antithrombotic agents

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.5 mg - antithrombotic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoprostenol sodium 1.593mg equivalent to epoprostenol 1.5 mg - powder for injection - 1.5 mg - active: epoprostenol sodium 1.593mg equivalent to epoprostenol 1.5 mg excipient: arginine sodium hydroxide sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii and iv patients with: · idiopathic pulmonary arterial hypertension · familial pulmonary arterial hypertension · pulmonary arterial hypertension asscociated with the scleroderma spectrum of diseases.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoprostenol sodium 531ug equivalent to epoprostenol 500 mcg - powder for injection - 500 mcg - active: epoprostenol sodium 531ug equivalent to epoprostenol 500 mcg excipient: arginine sodium hydroxide sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii and iv patients with: · idiopathic pulmonary arterial hypertension · familial pulmonary arterial hypertension · pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

United States - English - NLM (National Library of Medicine)

actelion pharmaceuticals us, inc. - epoprostenol (unii: dcr9z582x0) (epoprostenol - unii:dcr9z582x0) - epoprostenol 500000 ng in 10 ml - veletri is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise capacity. studies establishing effectiveness included predominantly patients with nyha functional class iii–iv symptoms and etiologies of idiopathic or heritable pah or pah associated with connective tissue diseases. a large study evaluating the effect of epoprostenol on survival in nyha class iii and iv patients with congestive heart failure due to severe left ventricular systolic dysfunction was terminated after an interim analysis of 471 patients revealed a higher mortality in patients receiving epoprostenol plus conventional therapy than in those receiving conventional therapy alone. the chronic use of veletri in patients with congestive heart failure due to severe left ventricular systolic dysfunction is therefore contraindicated. some patients with pulmonary hypertension have developed pulmonary edema during dose initiation, which may be associated with pulmonary veno-occlusive disease. vele

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - epoprostenol sodium - powder for solution for infusion - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - epoprostenol sodium - powder for solution for infusion - 1.5mg

Canada - English - Health Canada

janssen inc - epoprostenol (epoprostenol sodium) - powder for solution - 0.5mg - epoprostenol (epoprostenol sodium) 0.5mg - vasodilating agents